Annals of internal medicine
-
Comment Randomized Controlled Trial
In factor Xa inhibitor-related acute ICH, andexanet vs. usual care improved hemostatic efficacy but increased thrombotic events.
Connolly SJ, Sharma M, Cohen AT, et al; ANNEXA-I Investigators. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med. 2024;390:1745-1755. 38749032.
-
Comment Randomized Controlled Trial
In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109-121. 38785209.
-
Comment Randomized Controlled Trial
In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.
Meissner WG, Remy P, Giordana C, et al; LIXIPARK Study Group. Trial of lixisenatide in early Parkinson's disease. N Engl J Med. 2024;390:1176-1185. 38598572.
-
Comment Randomized Controlled Trial
After ACS, telemedicine-based care with remote patient monitoring vs. usual care reduced hospital readmissions at 6 mo.
Alshahrani NS, Hartley A, Howard J, et al. Randomized trial of remote assessment of patients after an acute coronary syndrome. J Am Coll Cardiol. 2024;83:2250-2259. 38588928.
-
Randomized Controlled Trial Multicenter Study
Pain Reduction With Oral Methotrexate in Knee Osteoarthritis : A Randomized, Placebo-Controlled Clinical Trial.
Treatments for osteoarthritis (OA) are limited. Previous small studies suggest that the antirheumatic drug methotrexate may be a potential treatment for OA pain. ⋯ Versus Arthritis.